Scancell Holdings plc Share Price
Stocks
SCLP
GB00B63D3314
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
London S.E.
09:05:27 07/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 9.800 GBX | +2.51% |
|
+0.51% | -1.01% |
| 19/08 | EARNINGS AND TRADING: Cooks sales up; Amcomri profit rises, debt falls | AN |
| 19/08 | UK Regulator Allows Scancell Holdings to Launch Late-stage Trial for Advanced Melanoma Therapy | MT |
| Market Cap | 12Cr 16Cr 14Cr 13Cr 22Cr 1.52TCr 22Cr 154.38Cr 59Cr 779.3Cr 60Cr 59Cr 2.48TCr | P/E 2026 * |
-6.55x | P/E 2027 * | -12.4x |
|---|---|---|---|---|---|
| Enterprise Value | 13Cr 17Cr 15Cr 14Cr 24Cr 1.65TCr 24Cr 167.92Cr 65Cr 847.63Cr 66Cr 64Cr 2.7TCr | EV / Sales 2026 * |
103x | EV / Sales 2027 * | 56.1x |
| Free-Float |
96.87% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| SCLP | Delayed | |
OTC Markets
| SCNLF | Delayed | |
|
Deutsche Boerse AG
| SCP | Delayed |
Last Transcript : Scancell Holdings plc
| 1 day | +2.51% | ||
| 1 week | +0.51% | ||
| Current month | +0.51% | ||
| 1 month | +3.16% | ||
| 3 months | -56.64% | ||
| 6 months | -23.74% | ||
| Current year | -1.01% |
| 1 week | 9.5 |  | 9.9 |
| 1 month | 9.4 | | 10 |
| Current year | 9.3 | | 29.5 |
| 1 year | 7.86 | | 29.5 |
| 3 years | 7.26 | | 29.5 |
| 5 years | 7.26 | | 29.5 |
| 10 years | 0.11 | | 29.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Linda Durrant
CEO | Chief Executive Officer | 69 | 28/07/2021 |
| Chief Executive Officer | 64 | 18/11/2024 | |
David Schilansky
DFI | Director of Finance/CFO | 50 | 24/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Linda Durrant
BRD | Director/Board Member | 69 | 17/11/2010 |
Ursula Ney
BRD | Director/Board Member | 74 | 23/10/2019 |
Susan Davies
BRD | Director/Board Member | 64 | 24/09/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 16/09/25 | Vulpes Investment Management Pte Ltd.
| Buy | Company | 31,50,000 | 0.3038% | |
| 08/08/25 | Vulpes Investment Management Pte Ltd.
| Buy | Company | 1,02,236 | 0.0099% | |
| 04/08/25 | Vulpes Investment Management Pte Ltd.
| Buy | Company | 44,00,000 | 0.4244% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.51% | +0.51% | +12.00% | +5.95% | 16Cr | |
| -1.16% | -3.97% | -2.91% | +13.00% | 4.89TCr | |
| -0.40% | +1.03% | +418.57% | +527.30% | 4.5TCr | |
| -1.42% | +2.30% | +42.67% | +22.37% | 4.41TCr | |
| -1.22% | -2.31% | +4.82% | +77.49% | 4.07TCr | |
| -0.96% | -2.31% | +15.75% | +45.41% | 3.35TCr | |
| -0.21% | +9.14% | - | - | 1.78TCr | |
| -0.35% | -1.56% | +21.42% | +120.75% | 1.65TCr | |
| -1.54% | -1.05% | +12.16% | +29.80% | 1.47TCr | |
| -1.65% | -1.03% | +75.93% | +41.12% | 1.38TCr | |
| Average | -0.64% | +0.24% | +66.71% | +98.13% | 2.75TCr | |
| Weighted average by Cap. | -0.99% | +0.05% | +88.91% | +128.35% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 12.5L 16.93L 14.56L 13.7L 23.38L 16Cr 23.45L 1.62Cr 62.43L 8.2Cr 63.51L 62.16L 26Cr | 24L 32.5L 27.95L 26.3L 44.89L 31Cr 45.02L 3.12Cr 1.2Cr 16Cr 1.22Cr 1.19Cr 50Cr |
| Net income | -1.92Cr -2.6Cr -2.24Cr -2.11Cr -3.6Cr -246.04Cr -3.61Cr -25Cr -9.61Cr -126.17Cr -9.77Cr -9.57Cr -401.61Cr | -82.37L -1.12Cr -95.91L -90.25L -1.54Cr -105.37Cr -1.55Cr -11Cr -4.11Cr -54Cr -4.18Cr -4.1Cr -171.99Cr |
| Net Debt | 1.04Cr 1.41Cr 1.21Cr 1.14Cr 1.95Cr 133.25Cr 1.95Cr 14Cr 5.2Cr 68Cr 5.29Cr 5.18Cr 217.5Cr | 1.59Cr 2.15Cr 1.85Cr 1.74Cr 2.97Cr 203.06Cr 2.98Cr 21Cr 7.93Cr 104.13Cr 8.07Cr 7.89Cr 331.46Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/26/07 | GBX 9.800 | +2.51% | 25,65,172 |
| 04/26/04 | GBX 9.560 | +0.10% | 7,91,040 |
| 03/26/03 | GBX 9.550 | -0.52% | 23,61,253 |
| 02/26/02 | GBX 9.600 | 0.00% | 16,30,091 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- SCLP Stock
Select your edition
All financial news and data tailored to specific country editions
